Surrogate biomarkers of outcome for wake-up ischemic stroke

Pablo Hervella1,2*, María Luz Alonso-Alonso1, María Pérez-Mato3, Manuel Rodríguez-Yáñez4, Susana Arias-Rivas4, Iria López-Dequidt4, José M. Pumar1,5, Tomás Sobrino6, Francisco Campos7, José Castillo1 and Ramón Iglesias-Rey1,2*

Abstract

Background: Wake-up ischemic stroke (IS) has been usually excluded from acute stroke therapy options for being outside of the safe treatment window. We identified risk factors, and clinical or molecular biomarkers that could be therapeutic targets for wake-up stroke prevention, thus hopefully leading to a decrease in its mortality and disability in medium to long-term outcome.

Methods: 4251 ischemic stroke (IS) patients from a prospectively registered database were recruited; 3838 (90.3%) had known onset-symptom time, and 413 (9.7%) were wake-up strokes. The main endpoint was to analyze the association between different serum biomarkers with wake-up IS episodes and their progression. Leukocytes count, serum levels of C-reactive protein, fibrinogen, interleukin 6 (IL-6), and vitamin D were analyzed as inflammation biomarkers; N-terminal pro-B-type Natriuretic-Peptide and microalbuminuria, used as atrial/endothelial dysfunction biomarkers; finally, glutamate levels as excitotoxicity biomarker. In addition, demographic, clinical and neuroimaging variables associated with the time-evolution of wake-up IS patients and functional outcome at 3 months were evaluated. Good and poor functional outcome were defined as mRS \( \leq 2 \) and mRS > 2 at 3 months, respectively.

Results: Wake-up IS showed a poorer outcome at 3-months than in patients with known on-set-symptom time (59.1% vs. 48.1%; \( p < 0.0001 \)). Patients with wake-up IS had higher levels of inflammation biomarkers; IL-6 levels at admission (51.5 ± 15.1 vs. 27.8 ± 18.6 pg/ml; \( p < 0.0001 \)), and low vitamin D levels at 24 h (5.6 ± 9.4 ng/ml; \( p < 0.0001 \)) are worthy of attention. In a logistic regression model adjusted for vitamin D, OR was 15.1; CI 95%: 8.6–26.3, \( p < 0.0001 \). However, we found no difference in vitamin D levels between patients with or without clinical-DWI mismatch (no: 18.95 ± 9.66; yes: 17.84 ± 11.77 ng/mL, \( p = 0.394 \)). No difference in DWI volume at admission was found (49.3 ± 96.9 ml in wake-up IS patients vs. 51.7 ± 98.2 ml in awake IS patients; \( p = 0.895 \)).

Conclusions: Inflammatory biomarkers are the main factors that are strongly associated with wake-up IS episodes. Wake-up IS is associated with lower vitamin D levels. These data indicate that vitamin D deficiency could become a therapeutic target to reduce wake-up IS events.

Keywords: Biomarker, Stroke prevention, Prognosis, Vitamin D, Wake-up stroke

Background

Between 8 and 39% of strokes are wake-up strokes i.e., they occur during sleep [1–3]. The concept of wake-up stroke emerged because of the limitations of the intravenous recombinant tissue plasminogen activator (rtPA) treatment (time window < 4.5) [2–5]. This means
that the time when patients were last known well is used as a reference time for the stroke onset. Consequently, wake-up ischemic stroke (IS) has been usually excluded from acute stroke therapy options for being outside of the safe treatment window. However, different comparisons between wake-up and awake ischemic strokes have demonstrated clinical and radiological similarities between them [5–7]. In this line, studies on the timing of the onset-symptoms of ischemic stroke determined that there is a peak incidence in the early morning hours, suggesting that many wake-up strokes probably occur close to awakening [8, 9]. Proposed physiologic mechanisms related to this type of stroke include sleep-disordered breathing, patent foramen ovale, new-onset atrial fibrillation, endothelial dysfunction, morning blood pressure surge, peak in pro-thrombotic factors and increased platelet aggregation [10–12].

Analyzing the possible risk factors related to these events, as well as the methods to determine stroke symptom onset time by using imaging techniques or biomarkers, is a clinical priority. As a result, different research works and clinical trials have recently been developed, performed in imaging-selected patients, which reported better functional outcome in terms of mRS and NIHSS in wake-up ischemic individuals [13–16].

In recent years, advanced neuroimaging techniques have led to the development of a variety of research works and clinical trials seeking to include many of these patients with undetermined stroke onset in reperfusion therapies. To replace the old onset time window concept, tissue time window was based on brain tissue post-ischemic changes under the guidance of neuroimaging, mainly through Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) [17–19]. In this sense, WAKE-UP trial demonstrated that intravenous thrombolysis with alteplase resulted in a better functional outcome than treatment with placebo among acute ischemic stroke patients with unknown onset-symptom time based on MRI guide (DWI-FLAIR mismatch) [13, 14]. The EXTEND trial, based on CT perfusion or PWI-DWI MRI, found efficacy in rtPA treatment in patients with a favorable perfusion imaging profile 4.5 to 9 hours after stroke onset or on awakening [15]. Another single-center study suggested that thrombolytic therapy is effective in reducing infarct volume and improve functional outcome without increasing hemorrhagic transformation in patients with wake-up strokes selected by CT [16].

Other clinical aspects and factors that can help understand the mechanisms behind wake-up stroke and prevent its occurrence or its consequences are less known. In line, the cerebrovascular endothelium represents a biological and mechanical barrier between the cerebral and vascular compartments, where the endothelial dysfunction has been related to wake-up IS episodes [20, 21]. Most neurovascular risk factors, both traditional and newly identified, are linked to endothelial dysfunction in a cumulative manner, such as vitamin D deficiency. Vitamin D insufficiency has been associated to major chronic diseases such as cardiovascular and neurological disorders, diabetes, and cancer, all of which are linked to oxidative stress, inflammation, and aging [22]. It would be beneficial to identify clinical or biological markers related to the cardiovascular system (inflammation, excitotoxicity, endothelial and atrial dysfunction biomarkers), as well as risk factors that could become therapeutic targets for the prevention of wake-up stroke, resulting in lower mortality and disability in the medium to long term. We hypothesized that elevated serum levels of inflammation, excitotoxicity, endothelial and atrial dysfunction biomarkers might be involved in a higher frequency of wake-up IS episodes. In the present study, we looked at clinical factors to identify biomarkers associated to wake-up IS events, with a particular focus on vitamin D’s role.

**Methods**

**Patient selection**

For this study, the inclusion criteria were the following: IS patients confirmed by neuroimaging, attended by a neurologist according to national and international guidelines [23] and admitted to the Stroke Unit, and prospectively registered in an approved data bank. This data bank contains demographic, clinical, analytical and imaging variables for stroke patients treated in the Stroke Unit. This data bank has been pseudomised and communicated to the Hospital Management for its use for research purposes. Exclusion criteria were the following: 1) death during the first 24 hours; 2) transfer of the patient to other health care center; 3) lack of at least two neuroimaging studies in the first week; 4) known chronic inflammatory or infectious diseases (fever of unknown origin (axillary temperature > 37.5°C), inflammatory or infectious disease, etc); and 5) loss of follow-up (personal interview or telephone) at 3 months. The analysis of the data for this study was retrospective (January 2008–December 2017). All patients or their relatives signed the informed consent for inclusion in the registry and for anonymous use.

**Study design**

The main objective of this study was to analyze the association between inflammation, excitotoxicity, endothelial and atrial dysfunction biomarkers with wake-up IS episodes. As a secondary objective, we analyzed demographic, clinical and neuroimaging variables associated with the time-evolution of wake-up IS patients and functional outcome at 3 months.
Demographic and clinical variables
We defined wake-up IS as an ischemic stroke that is associated with neurological symptoms on awakening. By definition, the patient’s last-know-well time corresponds to the onset of sleep on the evening before event [2]. The demographic variables evaluated were: age, history of high blood pressure (at least 2 blood pressure measurements > 140/85 mmHg or under antihypertensive treatment), diabetes (previous diagnosis or under anti-diabetic treatment), smoking (habitual smoker or up to the previous half year), alcohol consumption (> 350 g of alcohol/week), dyslipidemia (at least a previous measurement of total cholesterol > 230 mg/dL or lipid lowering therapy), coronary disease, peripheral arterial disease, atrial fibrillation, carotid stenosis, hemodynamic carotid stenosis, occlusion/carotid sub-occlusion, prior transient ischemic attack, and treatment with anticoagulants / antiplatelets.

As clinical variables we analyzed the National Institute of Health Stroke Scale (NIHSS) [24] at admission, at 24 h, at discharge and at 3 months, previous and at 3-months±15 days modified Rankin Scale (mRS) [25], time detection-emergencies (time between the moment of the identification of the symptoms (not the beginning of the stroke) and the attention in the emergency room by a neurologist of the Stroke Unit), axillary temperature at admission, reperfusion treatments (intravenous or intravenous fibrinolysis, thrombectomy, and both processes), and time from detection to rtPA treatment. Good and poor functional outcome were defined as mRS score of ≤ 2 and mRS > 2 at 3 months, respectively. We defined early neurological improvement as a decrease ≥ 8 points in the NIHSS in the first 24 hours with respect to baseline NIHSS score. By contrast, early neurological deterioration was defined as an increase of four points in the first 48 hours (≥ 4 points). Both scales were evaluated by internationally certified neurologists and supervised by the same neurologist.

Neuroimaging studies
Neuroimaging studied in IS included the baseline infarct volume (DWI-lesion) and the presence of clinical-DWI mismatch (defined as NIHSS ≥8 and DWI volume ≤ 25 ml) [26]. Lesion volumes were calculated by using ABC/2 method [27] until 2016 and through automated planimetric method afterwards. IS etiology was evaluated according to TOAST criteria [28]. Expert neuroradiologists blinded to clinical data performed neuroimaging evaluations.

Molecular markers
Blood sample determinations that were carried out were as follows: erythrocyte sedimentation rate (ESR), glucose, triglycerides, glycated hemoglobin, LDL / HDL cholesterol. The inflammation markers included were fibrinogen, C-reactive protein, leukocytes, erythrocyte sedimentation rate, serum levels of interleukin 6 (IL-6) [29], vitamin D levels (25-Hydroxy-Vitamin D) at 24 hours [30]. N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) and microalbuminuria were the atrial dysfunction and endothelial markers determined, respectively [31]. Finally, serum levels of glutamate were evaluated as excitotoxicity marker [32].

Coagulation tests, hematometry, and biochemistry, were determined in the central laboratory of the Hospital blinded to clinical / neuroimaging data. Serum glutamate and IL-6 were performed in the Clinical Laboratory by researchers blinded to clinical / neuroimaging data. Blood samples, obtained from all patients at admission, were collected in test tubes, centrifuged at 3000 g during 15 min and immediately frozen / stored (at −80 °C).

Serum concentrations of IL-6 were determined by enzyme linked immunosorbent assay (ELISA) technique following manufacturer’s instructions (BioLegend, San Diego, USA), minimum assay sensitivity 1.6 pg/ml with an intra- and inter-assay coefficient of variation (5.0% vs. 6.8%). Serum glutamate concentration was determined by high performance liquid chromatography (1260 Infinity II, Agilent Technologies, Santa Clara, California, USA) using the AccQ-Tag™ Precolumn derivatization method for amino acid analysis (Waters, Milford, MA, USA), following a previously described method [33]. Biomarkers were evaluated within the first 3 months after blood sample collection and store. However only in 61.2% of patients serum glutamate was analyzed, IL-6 in 80.2% of patients and vitamin D in 79.8% of patients.

Statistical analysis
Results were described as mean ± standard deviation or the median [range] according to the type of distribution obtained by the Kolmogorov-Smirnov test for a sample with Lilliefors (correction of significance). Qualitative variables (factors) were described as percentages (%). The significance of the differences was estimated using the student’s t-test / the Mann-Whitney U-test. For the differences we used the chi-square test and, if applicable, the uncertainty coefficient.

In order to evaluate the independent variables associated with wake-up IS a multiple regression models were used, identifying continuous / categorical variables. First, we performed logistic regression models including variables (factors) with significant differences (p < 0.05) in univariate studies grouped according to demographic, clinical and neuroimaging variables. With the selected factors, a new logistic regression model was developed,
including the result of the biomarkers analyses. Bivariate correlations were performed using Spearman or Pearson’s coefficients. Based on the relationship between inflammation and vitamin D levels previously described [34, 35], two models for multivariate analyses with or without the value of IL-6 as an independent variable were performed. In the first model we evaluated if low vitamin D levels were more frequent in wake-up IS patients. The inclusion of IL-6 levels in the second model helped to confirm that this effect is dependent on increased inflammation.

To detect the capacity of vitamin D to categorize the values related with wake-up IS, Receiver Operating Characteristic (ROC) curves were evaluated, converting continuous variables into categorical ones for a value that offers maximum sensitivity / specificity. In turn, clinical-DWI mismatch and early neurological improvement relationship patients with IS according to vitamin D levels were evaluated taking into account a logistic regression model adjusted for age, previous mRS, temperature, C-reactive protein, NIHSS on admission and fibrinolytic treatment. Results were showed as odds ratio (OR) with 95% confident intervals (CI 95%). A p value < 0.05 was considered statistically significant. Data were analyzed using IBM SPSS_v.25 (IBM, Chicago, IL, USA) for Mac.

Results

Four thousand seven hundred eighty-six patients were enrolled for the present study. We excluded 97 patients who died during the first 24 hours, 118 who were transferred to other health care center, 33 known chronic inflammatory or infectious diseases, and 287 with no follow-up at 3 months. The final recruited sample was therefore 4251 IS patients eligible for the analysis. Of these IS, 3838 (90.3%) had a known onset-symptom time and 413 (9.7%) were wake-up strokes (mean ages 72.0 ± 13.8 and 71.9 ± 15.7, respectively). The demographic, clinical, neuroimaging, molecular and outcome variables for patients with awake versus and wake-up IS patients are detailed in Table 1.

Demographic, clinical, and neuroimaging variables

Wake-up stroke patients were younger, showed a higher proportion of atrial fibrillation, hyperlipidemia, or treatment with anticoagulants. No significant differences were found for sex, smoking and alcohol use, as well for other risk factors. According to clinical variables, wake-up IS patients showed a higher proportion of previous poor functional outcome [0 [0, 2] vs. 0 [0, 1], p < 0.0001], higher NIHSS at admission [18 [13, 20] vs. 16 [12, 20], p = 0.013], at 24 hours [8 [4, 14] vs. 7 [3, 13], p = 0.003], and at discharge [9 [3, 14] vs. 7 [2, 12], p < 0.0001]. As to early neurological improvement and early neurological deterioration in reperfused patients, there were no significant differences associated to time from stroke onset among patients. Finally, wake-up IS patients showed poor functional outcome at 3months (59.1% vs. 48.1%, p < 0.0001), and higher mRS [3 [1, 4] vs. 2 [0, 3], p < 0.0001]. Figure 1a-b details the NIHSS evolution at different time-points between unknown-onset and known-onset IS patients, and the distribution of the mRS scores categorized by the stroke onset time.

Results were showed as odds ratio (OR) with 95% confident intervals (CI 95%). A p value < 0.05 was considered statistically significant. Data were analyzed using IBM SPSS_v.25 (IBM, Chicago, IL, USA) for Mac.

Association between wake-up IS and different biomarkers

Molecular markers analysis indicated that wake-up IS patients had higher levels of inflammation variables (fibrinogen, leukocytes, C-reactive protein, erythrocyte sedimentation rate, IL-6, and vitamin D), and atrial dysfunction marker (NT-proBNP), highlighting the increased levels of IL-6 at admission (51.5 ± 15.1 pg/ml vs. 27.8 ± 18.6 pg/ml; p < 0.0001), as well as the low serum vitamin D levels (5.6 ± 5.8 ng/ml vs. 19.2 ± 9.4 ng/ml; p < 0.0001). In contrast, there were no stroke onset time differences related to the excitotoxicity marker glutamate at admission (266.8 ± 99.1 μM in wake-up IS patients vs. 267.2 ± 134.7 μM in awake IS patients; p = 0.124), and at 24 hours (136.7 ± 48.3 μM in wake-up IS patients vs. 131.8 ± 80.0 μM in awake IS patients; p = 0.198).

From the adjusted logistic regression model detailed in Table 2, Model A, we determined that wake-up IS is independently associated with the following inflammation markers; temperature (OR: 2.15; CI 95%: 1.77–2.61,
Table 1  Univariate analysis. Demographic, clinical, neuroimaging, molecular and outcome for patients with awake and wake-up IS (n = 4251)

| Demographic variables                              | Awake IS (n = 3838) | Wake-up IS (n = 413) | p value  |
|----------------------------------------------------|---------------------|----------------------|----------|
| Age, years                                         | 72.0 ± 13.8         | 71.9 ± 15.7          | 0.003    |
| Female gender, %                                   | 45.3                | 48.2                 | 0.275    |
| Arterial hypertension, %                           | 62.7                | 64.2                 | 0.592    |
| Diabetes, %                                        | 24.2                | 26.4                 | 0.335    |
| Smoking, %                                         | 16.0                | 17.7                 | 0.399    |
| Alcohol consumption, %                             | 11.5                | 12.1                 | 0.686    |
| Hyperlipidemia, %                                  | 33.6                | 39.5                 | 0.019    |
| Peripheral arterial disease, %                     | 5.8                 | 4.1                  | 0.178    |
| Ischemic heart disease, %                          | 11.0                | 11.6                 | 0.741    |
| Atrial fibrillation, %                             | 20.3                | 25.9                 | 0.011    |
| Heart failure, %                                   | 4.0                 | 5.8                  | 0.092    |
| Previous carotid stenosis, %                       | 1.5                 | 0.5                  | 0.119    |
| Ipsilateral hemodynamic carotid Stenosis, %        | 17.0                | 20.7                 | 0.510    |
| Occlusion/carotid sub-obclusion, %                 | 15.1                | 15.4                 | 0.897    |
| Previous transient ischemic attack, %             | 5.0                 | 3.4                  | 0.184    |
| Previous antiaggregants, %                         | 23.8                | 25.4                 | 0.466    |
| Previous anticoagulants, %                         | 7.5                 | 12.3                 | 0.001    |
| Clinical, Neuroimaging features                    |                     |                      |          |
| mRS (Previous)                                     | 0 [0, 1]            | 0 [0, 2]             | <0.0001  |
| NIHSS (at admission)                               | 16 [12, 20]         | 18 [13, 20]          | 0.013    |
| NIHSS (at 24 h)                                    | 7 [3, 13]           | 8 [4, 14]            | 0.003    |
| NIHSS (at discharge)                               | 7 [2, 12]           | 9 [3, 14]            | <0.0001  |
| Time detection (awakening)-emergencies, minutes    | 237.4 ± 164.2       | 293.5 ± 112.8        | 0.137    |
| Maximum axillary temperature 24 h, °C              | 36.3 ± 0.6          | 36.8 ± 0.6           | <0.0001  |
| Systemic fibrinolysis, %                           | 18.3                | 4.4                  | <0.0001  |
| Thrombectomy, %                                    | 4.4                 | 7.7                  | 0.089    |
| Endovascular treatment, %                          | 4.1                 | 3.4                  | 0.599    |
| Time detection-rtPA, min                           | 172.1 ± 78.3        | 186.1 ± 91.5         | 0.079    |
| DWI volume, ml                                     | 51.7 ± 98.2         | 49.3 ± 96.9          | 0.895    |
| Clinical-DWI mismatch, %                           | 15.1                | 17.9                 | 0.419    |
| TOAST criteria                                     |                     |                      | 0.215    |
| - Atherothrombotic, %                              | 23.1                | 20.8                 |          |
| - Cardioembolic, %                                 | 36.9                | 37.5                 |          |
| - Lacunar, %                                       | 8.5                 | 6.1                  |          |
| - Indeterminate, %                                 | 30.2                | 34.1                 |          |
| - Others, %                                        | 1.2                 | 1.5                  |          |
| Molecular markers                                  |                     |                      |          |
| Blood glucose (at admission), mg/dl                | 142.8 ± 62.7        | 142.2 ± 54.5         | 0.815    |
| Glycosylated hemoglobin, %                         | 6.3 ± 1.4           | 6.1 ± 1.3            | 0.326    |
| Erythrocyte sedimentation rate, mm                 | 26.4 ± 23.5         | 33.4 ± 23.8          | <0.0001  |
| LDL cholesterol, mg/dl                            | 106.4 ± 34.4        | 110.4 ± 39.1         | 0.129    |
| HDL cholesterol, mg/dl                            | 43.7 ± 17.2         | 42.2 ± 10.7          | 0.052    |
| Triglycerides, mg/dl                               | 113.9 ± 54.8        | 117.5 ± 65.9         | 0.892    |
| Leukocytes at admission, × 10^3/ml                 | 9.1 ± 3.2           | 10.1 ± 3.1           | <0.0001  |
| Fibrinogen at admission, mg/dl                     | 445.0 ± 104.4       | 465.3 ± 94.6         | 0.001    |
| C-reactive protein at admission, mg/l              | 3.4 ± 4.1           | 6.2 ± 3.6            | <0.0001  |
| IL-6 at admission, pg/ml                           | 27.8 ± 18.6         | 51.5 ± 15.1          | <0.0001  |
fibrinogen (OR: 0.99; CI 95%: 0.99–1.00, p = 0.013), C-reactive protein (OR: 1.14; CI 95%: 1.01–1.17, p < 0.0001), and vitamin D (OR: 0.75; CI 95%: 0.71–0.79, p < 0.0001). However, if we include the serum IL-6 levels in the model, the significance of the previous inflammation markers almost completely disappears, but it is significant for the IL-6 (OR: 1.1; CI 95%: 1.04–1.18, p = 0.002) as we can see in Table 2, Model B. Then, high plasma levels of IL-6 are associated with an increased risk of presenting a wake-up IS; the inclusion of IL-6 levels cancels the association of vitamin D levels with stroke upon waking. In Fig. 2, an association between vitamin D and serum levels of IL-6 at admission for wake-up and awake IS patients was showed. Low vitamin D levels were related with elevated serum levels of IL-6.

### Wake-up IS stroke risk and vitamin D levels

We found a significant association between wake-up IS patients and low serum vitamin D levels (9–14 ng/ml, p < 0.0001). Figure 3a details the distribution of vitamin D level quartiles for both groups of stroke patients studied. The ROC curve analysis of vitamin D concentrations for wake-up IS showed an area under the curve of 0.908; CI 95%: 0.877–0.938; p < 0.0001 (Fig. 3b). For a cut-off point of vitamin D levels ≤ 9 ng/ml the sensitivity is 88% and the specificity is 75%. On the other hand, vitamin D levels ≤14 ng/mL determine a sensitivity of 64% and a specificity of 93%. In a logistic regression model adjusted only for vitamin D, we found that serum vitamin D concentrations ≤9 ng/ml multiplied by 15 the risk of suffering a wake-up IS (OR: 15.1; CI 95%: 8.6–26.3, p < 0.0001).

In turn, vitamin D levels in patients without early neurological improvement were 15.45 ± 9.66 ng/mL, and 24.84 ± 11.77 ng/mL in those who improved early (p = 0.032). In a logistic regression model to analyse variables influencing early neurological improvement, vitamin D levels showed an association with an OR 1.16;
CI 95%: 1.02–1.39, \( p < 0.0001 \) in a model adjusted for age, previous mRS, temperature, C-reactive protein, NIHSS on admission and fibrinolytic treatment. However, we found no difference in vitamin D levels between patients with or without clinical-DWI mismatch (no: 18.95 \( \pm \) 9.66; yes: 17.84 \( \pm \) 11.77 ng/mL, \( p = 0.394 \)). This result is reflected in Fig. 4, where we detail the correlation between clinical-DWI mismatch and early neurological improvement in both groups of patients with IS according to the following criteria; 9 ng/ml \( \leq \) serum vitamin D levels <9 ng/ml. As we can see, higher concentrations of this vitamin are clearly associated with a neurological improvement in the patients with IS.

**Discussion**

In this study, clinical variables, neuroimaging features and biomarkers associated to inflammation, atrial dysfunction and endothelial or excitotoxicity were evaluated in order to characterize wake-up IS patients. In our series of patients with acute IS (\( n = 4251 \)), who received appropriate treatment according to clinical management guidelines, wake-up episodes occurred in 9.7% of patients. In line with previous studies, we can say that wake-up stroke patients showed an elevated severity at admission [5–7, 36], but their evolution over
3 months was similar to awake IS patients. No difference was found in DWI volume at admission and in clinical DWI mismatch in both group of patients. Findings that support the current trend that MRI or CT scan could be the best methods for extending the time window for wake-up IS patients [17–19].

The results of our study showed that wake-up IS events were independently associated with inflammation markers such as temperature, fibrinogen and C-reactive protein; however, this association was in turn, dependent on low serum vitamin D levels. Thus, the high levels of inflammatory markers in patients with wake-up stroke could be related to low vitamin D levels. To our knowledge, low levels of vitamin D have been associated with increased cardiovascular mortality, cancer incidence [37], autoimmune diseases such as multiple sclerosis [38], poor prognosis of stroke [39]. Clinical studies have demonstrated that a low serum level of vitamin D is associated with higher risk of stroke and negatively impacts recovery and mortality from stroke [24]. Moreover, a recent study has demonstrated an inverse association with IL-6 and high sensitivity C-reactive protein levels, suggesting a potential anti-inflammatory role for vitamin D in stroke individuals [30, 39]. On the other hand, preclinical data suggest that acute administration of vitamin D can limit infarct progression by modulating

Fig. 2 Association between vitamin D and serum levels of IL-6 at admission for wake-up and awake IS patients

Fig. 3 a Distribution of serum vitamin D levels quartiles for both IS patient groups. b ROC curve analysis to establish the sensitivity and specificity of serum vitamin D levels to predict wake-up IS risk. The cut-off point of vitamin D that optimally predicted a wake-up stroke was 9 ng/ml (area under curve 0.908, sensitivity 88%, specificity 75%, p<0.0001)
post-stroke brain inflammation. Supplementation with vitamin D reduced infarct volume by 50%, reduced of pro-inflammatory mediators IL-6, IL-1β, IL-23a, TGF-β and NADPH oxidase-2 in brains of mice, and increased the expression of the T-regulatory cell marker, Forkhead box-P3 (FoxP3) [40]. The impact of vitamin D deficiency in cerebrovascular diseases may adversely affect endothelial cell function and vascular homeostasis through pleiotropic pro-oxidant (endothelial nitric oxide synthase (eNOS), reactive oxygen species (ROS), upregulation of NADPH oxidases (NOXs)) and pro-inflammatory effects (inflammatory cytokines, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B), matrix metalloproteinases (MMPs)). In turn, these effects related to vitamin D deficiency can enhance tissue sensitivity to oxidative stress and inflammatory events, with consequent increased susceptibility to the onset and severity of stroke events [22].

To our knowledge, this study is the first study about the difference of vitamin D level between wake-up stroke and awake stroke. We have found that serum vitamin D levels may be associated with an increased risk of wake-up IS, in particular serum vitamin D levels ≤9 ng/ml multiply by 15 the risk of suffering an ischemic stroke during sleep. The cardiovascular system is known to be particularly sensitive to vitamin D levels, which can lead to endothelial dysfunction and vascular abnormalities through a variety of mechanisms, including cytokine release, superoxide migration inhibition, and monocyte adhesion and migration [22]. Taking into account that one of the physiological mechanisms involved in wake-up stroke is the endothelial dysfunction, we hypothesized that the endothelial dysfunction could be the “meeting point”, and the endothelium could be the link between risk factors and vascular lesion due vitamin D deficiency. This, however, will require further studies.

On the other hand, when IL-6 was included in the multivariate regression model, the significance of the markers including vitamin D disappeared. The relationship between inflammation and vitamin D levels is well known [34, 35], so vitamin D could be an excellent therapeutic target to reduce inflammation. We can see that high serum levels of IL-6 are associated with an increased risk of waking-up IS and this risk is, to a large extent, independent of low serum vitamin D levels. Considering the clinical view, the diagnosis and monitoring of vitamin D deficiency could prove a preventive action in routine clinical practice to maintain optimal levels by means of adequate supplementation or healthy habits. However, further research is needed in this area because various factors might influence in the origin of deficiency of vitamin D levels, or an individual’s response to a particular dose of vitamin D (obesity, genetic factors, lifestyle, etc.) [22].

This study has the following limitations: First, it is a prospective single center study, although an elevate sample size were included. Second, despite having a very large total patient sample, IS groups were unbalanced. We consider, however, that it would be important to study the two types of stroke independently. Three, only in 61.2% of patients serum glutamate was analyzed, IL-6 in 80.2% of patients and vitamin D in 79.8% of patients. Four, the wake-up group’s pathophysiological link between inflammation and stroke could be due to causes other than vitamin D levels. Atrial fibrillation has recently been associated to increased systemic inflammation, and it was shown to be considerably more common in the wake-up stroke group in the current study.

Fig. 4 Clinical-DWI mismatch and early neurological improvement relationship patients with IS according to (a) vitamin D level < 9 ng/ml, and (b) vitamin D level > 9 ng/ml
(p = 0.011). However, clinical and analytical markers of inflammation (temperature, fibrinogen, C-reactive protein, and IL-6) were not found to be higher in wake-up patients with cardioembolic stroke in our data bank. Finally, IL-6, and serum glutamate determinations were not simultaneous. Different researchers performed the determinations, although always blinded to the clinical/ neuroimaging data, and supervised by the same senior researcher. In the same lines with the results for clinical and neurological data.

Conclusion
Wake-up strokes present significant physiological differences from conventional strokes. These differences could be used for reducing their risk of occurrence, facilitating their identification, and improving the care of these patients during their acute phase. The presence of inflammatory biomarkers is the main factor strongly associated with wake-up IS episodes. Serum vitamin D levels ≤ 9 ng/ml multiply by 15 the risk of suffering an ischemic stroke during sleep. While the benefit of vitamin D supplementation on cerebrovascular outcomes requires deeper study, the diagnosis and monitoring of vitamin D deficiency could be a therapeutic target to reduce wake-up ischemic stroke events. This, however, will require further studies.

Abbreviations
CT: Computed Tomography; DWI: Diffusion weighted image; eNOS: Endothelial nitric oxide synthase; ESR: Erythrocyte sedimentation rate; FOX-P3: Forkhead box-P3; IL-6: Interleukin 6; IS: Ischemic stroke; OR: Odds ratio; PWI: Perfusion weighted image; MMP: Matrix metalloproteinases; MRI: Magnetic Resonance Imaging; mRS: Modified Rankin Scale; NIHSS: National Institute of Health Stroke Scale; NT‑proBNP: N‑terminal pro‑B‑type Natriuretic‑Peptide; ROC: Receiver Operating Characteristic; ROS: Reactive oxygen species; rtPA: Intravenous recombinant tissue plasminogen activator.

Acknowledgements
Not Applicable.

Authors’ contributions
Organization and design of the study (JC, RIR, PH). Clinical data acquisition, recruitment, and evaluation of participants (MRY, SAR, ILD, JMP). Statistical analysis and graphical presentation (JC, RI). Manuscript drafting (JC, RIR, PH, MLAA). Critical revision and execution of the project (MPM, TS, JC, FC). Supervision, review and critique (JC, MRY, FC, TS, MLAA). All authors read, reviewed and agreed the manuscript version.

Funding
Spanish Ministry of Science and Innovation (SAF2017–84267‑R), Xunta de Galicia (Consellería de Educación:IN607A2018/3), Instituto de Salud Carlos III (ISCIII) (PI21/01256). This research was conducted in accordance with the Declaration of Helsinki of the World Medical Association (2008) and approved by the Ethics Committee of Santiago de Compostela: [2019/616]. Data analysis for this study was retrospective, from January 2008 to December 2017. Before the start of the study a written informed consent from all participants were obtained.

Availability of data and materials
Statistical analysis plan is available on request. Data bank is not available for legal and ethical reasons.

Declarations
Ethics approval and consent to participate
For this study, the inclusion criteria were the following: IS patients confirmed by neuroimaging, attended by a neurologist according to national and international guidelines and admitted to the Stroke Unit (Hospital Clínico Universitario de Santiago de Compostela (IDIS), Santiago de Compostela, Spain). Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. Hospital Clínico Universitario, Rúa Travesa da Choupana, s/n, 15706 Santiago de Compostela, Spain. Neurosurgery and Cerebrovascular Research Laboratory, Department of Neurology and Stroke Center, La Paz University Hospital, Neuroscience Area of IDiPaz Health Research Institute, Universidad Autónoma de Madrid, Madrid, Spain. Stroke Unit, Department of Neurology, Hospital Clínico Universitario, Santiago de Compostela, Spain. Department of Neuroradiology, Hospital Clínico Universitario, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. Neuroaging Laboratory (NEURAL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain. Translational Stroke Laboratory (TREAT), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.

Received: 13 February 2022 Accepted: 31 May 2022

Published online: 09 June 2022

References
1. Mackey J, Kleindorfer D, Sucharew H, Moomaw CJ, Kissela BM, Alwell K, et al. Population-based study of wake-up strokes. Neurology. 2011;76:1662–7. https://doi.org/10.1212/WNL.0b013e318219fb30.
2. Malhotra K, Liebeskind DS. Wake-up stroke: dawn of a new era. Brain Circ. 2016;2:72–9. https://doi.org/10.4103/2394‑8180.186266.
3. Stern GM, Van Hise N, Urbén LM, Korobey MJ, Pitlick JM, Crannage AJ. Thrombolytic therapy in wake-up stroke patients. Clin Neuropharmacol. 2017;40:140–6. https://doi.org/10.1097/WNF.0000000000000212.
4. Rodríguez-Castro E, López-Dequidt I, Santamaría-Cadavid M, Arias-Rivas S, Rodríguez-Yáñez M, Pumar JM, et al. Trends in stroke outcome in the last ten years in a European tertiary hospital. BMC Neurol. 2018;18:164. https://doi.org/10.1186/s12883‑018‑1164‑7.
5. Peter-Derek L, Derec L. Wake-up stroke: from pathophysiology to management. Sleep Med Rev. 2019;48:101212. https://doi.org/10.1016/j.smrv.2019.101212.
6. Rimmelle DL, Thomalla G. Wake-up stroke: clinical characteristics, imaging findings, and treatment option – an update. Front Neurol. 2014;5:35. https://doi.org/10.3389/fneur.2014.00035.
7. Denny MC, Boehme AK, Dorsey AM, George AJ, Yeh AD, Albright KC, et al. Wake-up strokes are similar to known onset morning strokes in severity and outcome. J Neurol Neurosurg Psychiatry. 2021;11:102. https://doi.org/10.1136/jnnp-2021-324891.

8. Marler AR, Price TR, Clark GL, Muller JE, Robertson T, Mohr JP, et al. Morning increase in onset of ischemic stroke. Stroke. 1989;20:473–6. https://doi.org/10.1161/01.str.20.4.473.

9. Elliott WJ. Circadian variation in the timing of stroke onset: a meta-analysis. Stroke. 1998;29:992–6. https://doi.org/10.1161/01.str.29.5.992.

10. Bremner WF, Soethem RB, Kanabrocki EL, Ryan M, McCormick JB, Dawson S, et al. Relation between circadian patterns in levels of circulating lipoprotein(a) fibrnogen, platelets, and related lipid variables in men. Am Heart J. 2000;139:164–73. https://doi.org/10.1067/mhj.2000.90324-7.

11. Omama S, Yoshida Y, Ogawa A, Onoda T, Okayama A. Differences in circadian variation of cerebral infarction, in-tracerebral haemorrhage and subarachnoid haemorrhage by situation at onset. J Neurol Neurosurg Psychiatry. 2006;77:1345–9. https://doi.org/10.1136/jnnp.2006.090373.

12. Butt MU, Zakaria M, Hussain HM. Circadian pattern of onset of ischemic and haemorrhagic strokes, and their relation to sleep/wake cycle. J Pak Med Assoc. 2009;59:129–32.

13. Thomalla G, Cheng B, Ebinger M, Tordias T, Wu O, Kim JS, et al. DWF-FLAIR mismatch for the identification of patients with acute ischemic stroke within 4.5 h of symptom onset (PRE-FLAIR): a multicenter observational study. Lancet Neurol. 2011;10:978–86. https://doi.org/10.1016/S1474-4422(11)70192-2.

14. Thomalla G, Simonsen CZ, Bouttie F, Andersen G, Berthezene Y, Cheng B, et al. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 2018;379:611–22. https://doi.org/10.1056/NEJMoa1804355.

15. Ma H, Campbell BCV, Parsons MW, Chui YI, Levi CR, Hsu C, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380:1795–803. https://doi.org/10.1056/NEJMoa1813046.

16. Furlanis G, Ajčević M, Stella AB, Cillotto T, Caruso P, Ridolfi M, et al. Early morning attenuation of endothelial function in healthy humans. Circulation. 2004;109(21):2507–10. https://doi.org/10.1161/01.CIR.0000128207.26863.C4.

17. Liebner S, Dijkhuizen RM, Svetlikova A, Plate KH, Agalliu D, Constantin G. Functional morphology of the blood-brain barrier in health and disease. Acta Neuropathol. 2018;135(3):311–36. https://doi.org/10.1007/s00401-018-1815-1.

18. Kim HA, Perrelli A, Ragni A, Retta F, Silva TM, Sobey CG, et al. Vitamin D deficiency and the risk of cerebrovascular disease. Antioxidants (Basel). 2018;7(4):327. https://doi.org/10.3390/antiox7040327.

19. European Stroke Organisation (ESO). Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis. 2008;25:457–507. https://doi.org/10.1159/000131083.

20. Montaner J, Álvarez-Sabin J. NIHSS stroke scale and its adaptation to Spanish. Neurologia. 2006;21:192–202.

21. Bonita R, Beagheleho R. Recovery of motor function after stroke. Stroke. 1988;19:1497–500. https://doi.org/10.1161/01.str.12.14.1497.

22. Dávalos A, Blanco M, Pedraza S, Leira R, Castellanos M, Pummar JM, et al. The clinical-DWI mismatch: a new diagnostic approach to the brain tissue at risk of infarction. Neurology. 2004;62:2187–92. https://doi.org/10.1212/00005390-0141127.ea.

23. Sims JR, Gharai LR, Schafer PW, Vangel M, Rosenthal ES, Lev MH, et al. ABC/2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes. Neurology. 2009;72:2104–10. https://doi.org/10.1212/WNL.0b013e3181aa5329.

24. Adams JP, Jr, Bendixen BH, Kapelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial TOAST. Trial of org 10172 in acute stroke treatment. Stroke. 1993;24:35–41. https://doi.org/10.1161/01.str.24.1.35.

25. Leira Y, Amiejeira P, Domínguez C, Minematsu K, Toyoda K. Periodontal inflammation is related to increased serum calctonin gene-related peptide levels in patients with chronic migraine. J Periodontol. 2019;90:1088–95. https://doi.org/10.1177/1744940017762664.

26. Wang Q, Zhu Z, Liu Y, Tu X, He J. Relationship between serum vitamin D levels and inflammatory markers in acute stroke patients. Brain Behav. 2018;8:e00885. https://doi.org/10.1002/brb3.885.

27. Rodríguez-Castro E, Hervella P, López-Dequidt I, Arias-Rivas S, Santamaria-Cadavid M, López-Loureiro I, et al. NT-pro-BNP: a novel predictor of stroke risk after transient ischemic attack. Int J Cardiol. 2020;298:93–7. https://doi.org/10.1016/j.ijcard.2019.06.056.

28. da Silva-Candal A, Pérez-Díaz A, Santamaría M, Correa-Paz C, Rodríguez-Yáñez M, Arádá A, et al. Clinical validation of blood/brain glutamate grabbing in acute ischemic stroke. Ann Neurol. 2018;84:260–27. https://doi.org/10.1002/ana.25286.

29. Campos F, Sobrino T, Ramos-Cabrer P, Castellanos M, Blanco M, Rodríguez-Yáñez M, et al. High blood glutamate oxaloacetate transaminase levels are associated with good functional outcome in acute ischemic. J Cereb Blood Flow Metab. 2011;31:1387–93. https://doi.org/10.1038/jcbfm.2011.4.

30. Gouni-Berthold I, Berthold HK. Vitamin D and vascular disease. Curr Vas Pharmacol. 2021;19:250–68. https://doi.org/10.2174/1757611618666200317151955.

31. Meca AD, Stefánescu S, Bogdan M, Turcu-Stoicla A, Nitu FM, Matei M, et al. Crosstalk between vitamin D axis, inflammation and host immunity mechanisms: a prospective study. Exp Ther Med. 2021;21:608.

32. Inoue Y, Miyashita F, Koga M, et al. Unclear-onsert intracerebral hemorrhage: clinical characteristics, hematoma features, and outcomes. Int J Stroke. 2017;12:961–8.

33. Tagliaabe E, Raimondi S, Gandini S, Vitamin D, cancer risk, and mortality. Adv Food Nutr Res. 2015;75:1–52. https://doi.org/10.1016/B978-0-12-801360-3.00003-8.

34. Alharbi FM. Update in vitamin D and multiple sclerosis. Neurosciences (Riyadh). 2015;20:329–35. https://doi.org/10.1177/1303189915571139.

35. Alferri DF, Lehmann MF, Oliveira SR, Flauzino T, Delongu F, Martins de Araújo MC, et al. Vitamin D deficiency is associated with acute ischemic stroke, C-reactive protein, and short-term outcome. Metab Brain Dis. 2017;32:493–502. https://doi.org/10.1007/s11011-016-9939-2.

36. Evans MA, Kim HA, Ling YH, Uong S, Venable S, De Silva TM, et al. Vitamin D3 supplementation reduces subsequent brain injury and inflammation associated with ischemic stroke. NeuroMolecular Med. 2018;20(1):147–59. https://doi.org/10.1007/s12017-018-8484-z.